Liver multiplex scanning shows to be a cost-effective alternative to liver biopsies to monitor patients with autoimmune hepatitis.

Oxford, England – () – A health economics study conducted by the Oxford Academic Health Sciences Network (AHSN) of the NHS in England showed that the Perspectum device liver The non-invasive AI-enhanced Liver Health Diagnostic Tool is a cost-effective alternative to painful and invasive liver biopsies to monitor disease activity and response to treatment in patients with autoimmune hepatitis (AIH).

Patients with AIH, a chronic condition, require lifelong treatment with corticosteroids and immunosuppressants. Their clinical management is challenging, with most patients experiencing frequent periods of remission, followed by flared disease activity – requiring close and continuous monitoring using liver biopsy to adjust drug dose. The expensive, invasive, and incomplete nature of liver biopsy, together with poor patient acceptance and associated safety risks, especially in children, drive the urgent need to replace it with cost-effective, non-invasive techniques that can accurately monitor disease activity and treatment response in AIH patients.

This new study published in the journal, BMJ is open, estimated significant cost savings of up to £336,926 for 100 patients over five years when monitoring liver biopsies were replaced by LiverMultiScan in AIH patient care pathways in NHS England. In addition to lowering healthcare costs, previously published evidence suggests that including LiverMultiScan in the clinical care of patients with AIH can improve clinical decision-making.1patient safety2experience3.

Mamta Bajre, MBBS, M.Sc. concluded that, “Non-invasive imaging with LiverMultiScan can detect the presence and extent of fibrous hepatitis in a risk-free manner, resulting in a lower frequency of liver biopsy for AIH patients.” Health Economics, lead author of the study and Oxford AHSN member at NHS England. Our study demonstrates that incorporating LiverMultiScan into the pathways of AIH patients results in significant cost savings for the NHS, while reducing hospitalization and management costs associated with liver biopsy. By eliminating the risks and complications associated with a liver biopsy, the LiverMultiScan device helps improve patient outcomes and experiences.”

Experienced hepatologists and AIH experts from St Mary’s Hospital – Imperial College NHS Foundation Trust, Oxford NHS Foundation Trust Hospitals and King’s College Hospital participated in the development of this economic modeling study, which was funded by the prestigious Innovate UK grant (104915) aimed at supporting the assessment Early economics of innovative medical technologies.

“Although liver biopsy is necessary for diagnosis, liver biopsy is not sustainable for long-term monitoring of patients with AIH. Factoring in the economic benefits of LiverMultiScan shown in this independent study with its potential to positively influence clinical management by detecting sub-clinical disease Predicting clinical outcomes, along with feedback from all stakeholders involved in patient care, I would say LiverMultiScan is probably one of the best,” said Elizabeth Chumpionda, PhD, a clinical scientist who leads research in AIH and other autoimmune liver diseases at Perspectum, The Monitoring Tools to Support the Management of Patients with AIH.

Read the full paper here.


  1. Heneghan, MA, et al. (2022). Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. Clinical MedicineAnd the 46101325.

  2. Thomaides-Brears, H., et al. (2021). Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis. Gastrointestinal diseases and sciencesAnd the 67(7), 3366-394.

  3. McKay, A, et al. (2021). Patient understanding and experience in non-invasive imaging diagnostic techniques and the course of the liver patient. Journal of patient-reported outcomesAnd the 5(1), 89.

About autoimmune hepatitis

Autoimmune hepatitis (AIH) is a chronic condition in which the immune system incorrectly identifies the liver as something “foreign” (such as a bacteria or virus) and attacks it, causing inflammation and infection of the liver. AIH disproportionately affects women and girls, and worse outcomes are seen in vulnerable communities with limited access to healthcare resources. Currently, there is no cure for AIH, and like other chronic diseases, lifelong management is required for most patients to reduce overactivity of the immune system and stop further living damage.

About LiverMultiScan®

LiverMultiScan is a new technology that addresses the unmet need for non-invasive techniques to diagnose and monitor patients with chronic liver diseases such as nonalcoholic steatohepatitis, autoimmune hepatitis, or viral hepatitis. The LiverMultiScan uses artificial intelligence-enhanced multifactorial magnetic resonance imaging (MRI) to accurately assess signs of liver disease by simultaneously measuring disease activity and severity (using MRI scale, cT1®), lipids, and iron content, providing a complete picture of health liver;

about perspective

Perspectum, a global medical technology company with offices in the UK, US, Portugal and Singapore, offers pioneering digital technologies that help clinicians deliver better care for patients with chronic metabolic diseases, multiple organ diseases and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians with quantitative health assessments that enable early detection, diagnosis, and targeted therapy. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale.

For additional information, please visit: Perspectum.comAnd the LinkedInAnd the FacebookAnd the Twitter